Prognostic and immunotherapeutic implications of histamine-related biomarkers in lung adenocarcinoma
- 1Department of Thoracic Surgery & Cardiovascular Surgery, The Affiliated Changsha Central Hospital of University of South China, Changsha, Hunan, China
Abstract
Background: Recent researches have revealed that histamine plays a critical role in promoting pathogenesis of cancers. However, the key histamine-related molecular signatures and their functional roles in lung adenocarcinoma (LUAD) remain largely unknown.
Methods: Differentially expressed analysis was conducted on transcriptome data to screen differentially expressed genes (DEGs) between LUAD and control (adjacent non-cancerous samples) groups. The differentially expressed histamine-related genes in LUAD were identified by intersecting DEGs and histamine-related genes. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses were applied to determine key signatures associated with LUAD prognosis. Subsequently, we constructed a histamine-related prognostic risk model, compared functional enrichment and immune cell infiltration, and predicted immunotherapeutic responses and chemotherapeutic sensitivities between two risk groups using gene set enrichment analysis (GSEA), CIBERSORT, and TIDE algorithms. Finally, we investigated the expression patterns and methylation levels of key signatures.
Results: Firstly, 24 candidate histamine-related genes in LUAD, which were involved in histamine transport/secretion and neurotransmitter receptor activity were identified. After univariate Cox regression and LASSO analyses, five histamine-related genes, including SLC18A2, CDT1, PLA2G3, TSPAN7 and BTK were identified as associated with LUAD prognosis. Specifically, CDT1 was up-regulated, while the other four genes were down-regulated in LUAD samples. By calculating the histamine-related risk score, a risk model with area under curve values >0.6 (up to 0.7) for 1-, 3-, and 5-year predictions in both training and validation sets was constructed and validated. Further enrichment analysis showed a relation between risk score and immune (immune cells, immunotherapy response), and we found that low-risk group was in a more immunoactive status. Importantly, low-risk patients were predicted to have better responses to immunotherapy, while high-risk group had greater sensitivity to crizotinib, docetaxel, erlotinib, gefitinib, paclitaxel and vinorelbine. Moreover, we identified that the DNA methylation profiles of these signatures were altered in LUAD.
Conclusion: In this study, we focused on histamine, identified histamine-related genes and developed a new prognostic model for LUAD, providing an important theoretical foundation and practical reference for pathogenesis and precision treatment of patients with LUAD.
Related
- Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications
- Immune remodeling in inflammatory bowel disease-associated colorectal cancer: Mechanisms and immunotherapeutic implications (Review)
- Prognostic and Spatial Organization of Tertiary Lymphoid Structures in Pancreatic Ductal Adenocarcinoma
- Prognostic significance and clinicopathologic prediction of tumor deposits in non-metastatic colon mucinous adenocarcinoma
- A pathomics model for predicting lactate-related prognostic risk groups and their biological mechanisms in lung adenocarcinoma
BibTeX
@article{chen2026prognostic,
title = {{Prognostic and immunotherapeutic implications of histamine-related biomarkers in lung adenocarcinoma}},
author = {Fancai Chen and Jinfeng Wang and Jicheng Yang and Yuexi Yuan and Hua Luo and Jianming Peng and Chengyi Yan and Zhang Zhang},
journal = {PeerJ},
year = {2026},
month = sep,
doi = {10.7717/peerj.21760},
url = {https://peerj.com/articles/21760},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic and immunotherapeutic implications of histamine-related biomarkers in lung adenocarcinoma
AU - Fancai Chen
AU - Jinfeng Wang
AU - Jicheng Yang
AU - Yuexi Yuan
AU - Hua Luo
AU - Jianming Peng
AU - Chengyi Yan
AU - Zhang Zhang
PY - 2026
DA - 2026/09/30
JO - PeerJ
DO - 10.7717/peerj.21760
UR - https://peerj.com/articles/21760
AB - Background: Recent researches have revealed that histamine plays a critical role in promoting pathogenesis of cancers. However, the key histamine-related molecular signatures and their functional roles in lung adenocarcinoma (LUAD) remain largely unknown. Methods: Differentially expressed analysis was conducted on transcriptome data to screen differentially expressed genes (DEGs) between LUAD and control (adjacent non-cancerous samples) groups. The differentially expressed histamine-related genes in LUAD were identified by intersecting DEGs and histamine-related genes. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses were applied to determine key signatures associated with LUAD prognosis. Subsequently, we constructed a histamine-related prognostic risk model, compared functional enrichment and immune cell infiltration, and predicted immunotherapeutic responses and chemotherapeutic sensitivities between two risk groups using gene set enrichment analysis (GSEA), CIBERSORT, and TIDE algorithms. Finally, we investigated the expression patterns and methylation levels of key signatures. Results: Firstly, 24 candidate histamine-related genes in LUAD, which were involved in histamine transport/secretion and neurotransmitter receptor activity were identified. After univariate Cox regression and LASSO analyses, five histamine-related genes, including SLC18A2, CDT1, PLA2G3, TSPAN7 and BTK were identified as associated with LUAD prognosis. Specifically, CDT1 was up-regulated, while the other four genes were down-regulated in LUAD samples. By calculating the histamine-related risk score, a risk model with area under curve values >0.6 (up to 0.7) for 1-, 3-, and 5-year predictions in both training and validation sets was constructed and validated. Further enrichment analysis showed a relation between risk score and immune (immune cells, immunotherapy response), and we found that low-risk group was in a more immunoactive status. Importantly, low-risk patients were predicted to have better responses to immunotherapy, while high-risk group had greater sensitivity to crizotinib, docetaxel, erlotinib, gefitinib, paclitaxel and vinorelbine. Moreover, we identified that the DNA methylation profiles of these signatures were altered in LUAD. Conclusion: In this study, we focused on histamine, identified histamine-related genes and developed a new prognostic model for LUAD, providing an important theoretical foundation and practical reference for pathogenesis and precision treatment of patients with LUAD.
SN - 2167-8359
ER -